These results provided the foundationfor an ongoing multicenter double blind placebo controlled Phase 2b study of 4doses of INT131 and pioglitazone comparator in T2DM patients, which is designedto rigorously test the SPPARM activity of INT131 for separation of PPARγ mediated efficacy in treating insulinresistance from TZD side effects. This evidence concerns the gene PPARG and type 2 diabetes mellitus.